De-escalation strategies in human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor–positive phase II randomized trial—efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 2017; 35: 3046-3054.

Published: 5th January 2018

Authors: Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S et al.


This study included 375 women with a particular subtype of breast cancer that is known to be less sensitive to chemotherapy. The combination of trastuzumab with endocrine therapy improved response from 15 to 41 per cent, P<0.001.

Pubmed Link

Your comments